ClinicalTrials.gg
Not yet recruitingNCT04685239Updated Mar 27, 2023

Dual Mobility Cup Versus Unipolar Cup

An interventional study of dual mobility cup and unipolar cup in Dislocation, Hip, sponsored by Northern Orthopaedic Division, Denmark. Not yet recruiting at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Northern Orthopaedic Division, Denmark · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The general purpose of this study is to examine whether the dual mobility cup (Novae® Serf) reduces the number of hip dislocations after total hip replacement, both early dislocation (≤1 year) and late dislocation (>1 year) after primary THR compared with a conventional cup design (Trabecular MetalTM Modular Acetabular System).

Read the detailed description

Surgery with THR for arthritis and other hip disorders has long been one of the most successful orthopedic surgical treatments. The majority of the patients gain pain relief and experience improved hip function. In 2017, a total of 10,691 THRs were implanted in Denmark (annual report 2018).

Hip dislocation is a known complication after THR. It is a painful condition which may have far-reaching consequences for the patient, who may experience both physical and mental discomfort. Ultimately, multiple hip dislocations may result in reoperation.

In the literature, the incidence of hip dislocation is reported at 2-6 %, and a more recent review reports a risk of 0.5-10 %.

In Denmark, recurrent hip dislocation is the cause of 21 % of the reoperations per year according to The Danish Hip Arthroplasty Register. According to the British National Joint Registry (NJR) and the Australian register (AOANJRR), hip dislocation is the cause of 15.5 % and 21 %, respectively, of the reoperations.

The best method to avoid reoperation due to instability is to choose the correct implant for the individual patient and thereby spare the patient of having to endure a painful complication and yet another procedure. There are multiple risk factors for instability after THR, and increased use of dual mobility cups (DMC) is already documented.

02

Conditions studied

  • Dislocation, Hip

Browse trials for

Keywords

  • dislocation, hip
  • thr
  • dual mobility cup
03

In context

Hip Dislocation

107 studies on the registry are indexed under Hip Dislocation; 36 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 86 across 64 interventional studies indexed under Hip Dislocation.

Browse Hip Dislocation studies →

Lead sponsor

Northern Orthopaedic Division, Denmark is the lead sponsor of 61 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with hip arthritis who are amenable to surgery with THR and age ≥ 65 years referred to the Department of Orthopedic Surgery at either Section Farsø, Frederikshavn Hospital or Aalborg University Hospital. Patients who are willing to participate in the trial and who give their written, after receiving oral and written information.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not wish to participate.
  • Sequelae of Calvé-Legg-Perthes' disease, caput necrosis, epiphysiolysis.
  • Proximal femoral or acetabular fracture.
  • Hip dysplasia with subluxation Crowe types III and IV.
  • Earlier hip bone surgery (excluding arthroscopic surgery).
  • Elective bilateral surgery.
  • If the patient's bone morphology is unsuitable for a cemented Exeter® femoral stem.
  • Patients with no e-mail.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Unipolar cup

    Patients randomized to receive a conventional unipolar acetabular cup

    Device: unipolar cup

  • Active comparator
    dual mobility cup

    Patients randomized to receive a double mobility acetabular cup

    Device: dual mobility cup

Interventions

  • Devicedual mobility cup

    The use of a Sunfit dual mobility cup

  • Deviceunipolar cup

    The use of a TMT cup

06

What researchers measure

Primary outcomes

  1. Early dislocation, Difference in dislocation within 1 year.

    The primary outcome is the difference in cumulative incidence proportion of dislocation between the 2 randomized groups within the first year after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.

    Time frame: 1 year after surgery

Secondary outcomes

  1. Difference in dislocation within 5 years

    The difference in cumulative incidence proportion of dislocation between the 2 randomized groups within 5 years after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.

    Time frame: 5 years after surgery

  2. Dislocation 10 year

    The difference in cumulative incidence proportion of dislocation between the 2 randomized groups within 10 years after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.

    Time frame: 10 years after surgery

  3. Prosthesis survival.

    Evaluated by the cumulative incidence of THR's reoperated within 1, 5 and 10 years after total hip replacement. The information will be collected from both the patient through questionnaires and from the Danish Hip Arthroplasty Register and the Danish National Patient Register.

    Time frame: 1, 5 and 10 year

  4. Patient reported outcome measure: European quality of life 5 dimensions (EQ-5D 5L)

    Patients will be scored with EQ-5D 5L preoperatively and at 1,5 and 10 years. It consists of 5 dimensions ranging from 1-5, with 1 being the best in each dimension. It also consist of a visual analog scale ranging from 0-100, 100 being the best imaginable health, The EQ VAS describes the respondents current overall health. Data will be showed as changes in health over time showing responses at baseline and at follow up or as frequencies and proportions reported by dimension and level.

    Time frame: 1, 5 and 10 years

  5. Patient reported outcome measure: Oxford Hip Score (OHS)

    Patients will be scored with OHS at baseline and at 1, 5 and 10 years. OHS is a patient-recorded outcome measure designed to assess the outcome of hip replacements. Its a score between 0-48 with 48 being the best.

    Time frame: 1, 5 and 10 years

  6. Patient reported outcome measures: The Copenhagen Hip and Groin Outcome Score (HAGOS)

    HAGOS pain subscale will be used to report pain pre and postoperatively. The score in the pain subscale ranges from 0 (extreme hip/groin problems) -100 (no hip/groin problems).

    Time frame: 1, 5 and 10 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04685239
Lead sponsor
Northern Orthopaedic Division, Denmark
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Apr 1, 2023 (estimated)
Primary completion
Jan 2025 (estimated)
Completion
Dec 2035 (estimated)
Last update
Mar 27, 2023

Study contacts

Anders Diernæs, MD
Contact
anders.diernaes@rn.dk
+4597662503
Thomas Jakobsen, MD, PhD
Contact
thomas.jakobsen@rn.dk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion